Biocodex
http://www.biocodex.com/en/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Biocodex
Takeda/Ovid Plan Phase III For Soticlestat In Dravet Syndrome, But Pull Back On LGS
A Phase II trial of the CH24H inhibitor showed a statistically significant benefit in children with the rare epilepsy syndrome Dravet Syndrome, but not in Lennox-Gastaut syndrome (LGS).
Keeping Track Of US FDA Decisions: COVID-Induced Complete Response Letter For Contepo; Safety Sinks Abicipar Pegol; Approvals For Fintepla and Gimoti
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Zogenix Risks Fintepla Uptake With Dravet Drug’s High Price
The average list price of $96,000 per year is three times the cost of GW’s competing drug Epidiolex, but Zogenix is betting that the reduction in seizures seen in clinical trials will justify the expense.
GW Pharmaceuticals Scores EU First For Cannabinoid Drug
GW Pharmaceuticals is pressing on with plans to launch its epilepsy treatment Epidyolex in the EU, starting with France and Germany.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- Nutraceuticals
- Specialty Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Algol Pharma Oy
- Biocodex, Inc.
- Biocodex S.A.
- Biocodex SA
- Laboratoires Biocodex